CMS: No Settlement Yet to Resolve Mylan’s Misclassification of the EpiPen

Mylan has not reached a settlement with the Justice Department to resolve allegations that it misclassified its allergy therapy the EpiPen for a Medicaid program, and as a result, underpaid state rebates, the Centers of Medicare and Medicaid said.
Source: Drug Industry Daily